Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

Dummer, R; Ascierto, PA; Gogas, HJ; Arance, A; Mandala, M; Liszkay, G; Garbe, C; Schadendorf, D; Krajsova, I; Gutzmer, R; Sileni, VC; Dutriaux, C; de Groot, JWB; Yamazaki, N; Loquai, C; Moutouh-de Parseval, LA; Pickard, MD; Sandor, V; Roberti, C; Fla

Dummer, R (reprint author), Univ Hosp Zurich, Skin Canc Ctr, Dept Dermatol, CH-8091 Zurich, Switzerland.

LANCET ONCOLOGY, 2018; 19 (10): 1315

Abstract

Background Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAF(V600)......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索